Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer

This study has been withdrawn prior to enrollment.
(Suspended due to change in development plans and investigator)
Sponsor:
Collaborator:
Mount Sinai School of Medicine
Information provided by (Responsible Party):
Momotaro-Gene Inc.
ClinicalTrials.gov Identifier:
NCT01197209
First received: September 3, 2010
Last updated: August 21, 2013
Last verified: August 2013

September 3, 2010
August 21, 2013
September 2010
December 2010   (final data collection date for primary outcome measure)
  • Maximum Tolerated Dose [ Time Frame: 7-days ] [ Designated as safety issue: Yes ]
    To define the Maximum Tolerated Dose (MTD) for intertumoral injection (IT) of Ad-REIC/Dkk-3 viral vector.
  • Safety evaluation of adverse drug experiences compared with historical precedence [ Time Frame: 28-days ] [ Designated as safety issue: Yes ]
    To assess the safety of in-situ therapy with REIC/Dkk-3 gene in prostate cancer patients with high risk of local recurrence after radical prostatectomy. Safety events will be evaluated and assessed with regards to causality and in comparison with historical precedence for this patient population.
Same as current
Complete list of historical versions of study NCT01197209 on ClinicalTrials.gov Archive Site
Pharmacodynamic Efficacy Markers [ Time Frame: 28-days ] [ Designated as safety issue: No ]
To assess the effectiveness of Ad-REIC/Dkk-3 in the treatment of prostate cancer as evaluated by the PSA biomarker and histologic examination of extracted prostate tissue.
Same as current
Not Provided
Not Provided
 
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
A Phase I Neoadjuvant Study of In-situ REIC/Dkk-3 Therapy Followed By Prostatectomy in Patients With High Risk Localized Prostate Cancer

This is a phase I neoadjuvant gene therapy followed by prostatectomy, open-label, dose-escalation trial for prostate cancer patients with high risk of local recurrence after radical prostatectomy. Patients entered into this trial will have Prostate Cancer of Clinical stage T1c, T2 or T3 with a Gleason Score of between 7 (4+3) and 10 at the time of enrollment. Patients will receive three 1 mL injections (3 mL total volume) of Ad-REIC/Dkk-3 into the prostate prior to undergoing a radical prostatectomy. Three patients will be treated at each dose level unless a dose-limiting toxicity (DLT) is observed or MFD (defined as 1 x 10e12 vp/treatment) is achieved with expansion for up to 6 more patients at the MTD or MFD.

This is a phase I neoadjuvant gene therapy followed by prostatectomy, open-label, dose-escalation trial for prostate cancer patients with high risk of local recurrence after radical prostatectomy. Patients entered into this trial will have Prostate Cancer of Clinical stage T1c, T2 or T3 with a Gleason Score of between 7 (4+3) and 10 at the time of enrollment.

Patients will receive three 1 mL injections (3 mL total volume) of Ad-REIC/Dkk-3 into the prostate under transrectal ultrasound-guidance (TRUS) and, patients will undergo a radical prostatectomy four weeks after the injection.

Patients will receive treatment at one of three dose levels in a sequential dose-escalating design.

Three patients will be treated at each dose level unless a dose-limiting toxicity (DLT) is observed or MFD (defined as 1 x 10e12 vp/treatment) is achieved. Enrollment will proceed to the next dose level if 0 of 3 patients experiences a DLT; if one of the first 3 patients experiences a DLT, three additional patients will be enrolled until a second patient experiences a DLT (which defines the toxic dose) or until six total patients have been treated at that dose level, whichever comes first. If a second DLT is not experienced within that cohort, dose escalation may continue.

Additional patients will be enrolled a minimum of 14 days after treatment of the first patient in the cohort (sentinel patient).

If 2 DLTs are observed within a cohort, enrollment into the cohort will cease and the dose level immediately preceding that dose will be determined to be the MTD. If 2 non-lethal DLTs are observed in Cohort 1, a lower dose cohort (Cohort -1) may be initiated.

Once the MTD is defined, an additional 3-6 patients may be enrolled at that dose level to further evaluate safety of the MTD.

Patients will undergo a scheduled radical prostatectomy approximately 4 weeks after the Ad-REIC/Dkk-3 injection. The prostate tissue removed will be retained and for those patients treated at the MTD, assessed for REIC expression and evidence of apoptosis by TUNEL staining.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
Biological: Ad-REIC/Dkk-3
REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
Experimental: Ad-REIC/Dkk-3 Arm
Active arm on Ad-REIC/Dkk-3
Intervention: Biological: Ad-REIC/Dkk-3
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male aged between 20 and 75 years (inclusive) with histologically documented clinically localized, adenocarcinoma of the prostate scheduled to undergo a radical prostatectomy.
  2. Patient with clinical stage T1c, T2 or T3 with Primary Gleason score of 4 [total Gleason score of between 7 (4+3) and 10] at time of assessment for this trial.
  3. Recent (≤ 3 months prior to study entry) negative bone scan and CT scan of abdomen/pelvis.
  4. Life expectancy of at least 10 years.
  5. In good general health, free from clinically significant illness or disease (as determined by medical/surgical history, physical examination, weight, 12-lead ECG, and clinical laboratory tests)
  6. Appropriate surgical candidate for radical prostatectomy and a performance status of ≤ 2 (Zubrod scale)
  7. Patients should have adequate bone marrow function defined as an absolute peripheral granulocyte count ≥ 1,500 and platelet count of ≥ 100,000, adequate hepatic function with a total bilirubin ≤ 1.5 mg/dl and ALT < 4x the upper limits of normal, adequate renal function defined as serum creatinine ≤ 2.0 mg/dl
  8. Body Mass Index ≥ 18 and ≤ 35 kg/m2
  9. Patients must have normal coagulation profile (PT, PTT) and no history of substantial non-iatrogenic bleeding diatheses. Use of anticoagulants is limited to local use only (for control of central line patency).
  10. Patient is willing to refrain from sexual activity or agrees to use a barrier contraceptive device (e.g. condom) after treatment with Ad-REIC/Dkk-3 and until the prostatectomy operation.
  11. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with the policies of the institution.

Exclusion Criteria:

  1. Previous or current hormonal treatment, chemotherapy, radiation therapy, immunotherapy or other investigational status drug within the past 4 weeks.
  2. Unable to tolerate transrectal ultrasound.
  3. Patients who are not appropriate surgical candidates for radical prostatectomy based on the evaluation of co-existent medical diseases and competing causes of death.
  4. Patients with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorders are not eligible.
  5. Patients who are HIV positive or have chronic hepatitis B or C infections are not eligible (because of possible immune effects of these conditions).
  6. Patients with a clinical history of primary or secondary immunodeficiency, autoimmune disease or patients taking immunosuppressive drugs such as corticosteroids continuously for > 4 months [> 5 mg hydrocortisone/day] are ineligible. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have a decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)
  7. As a result of medical review, physical examination, the Principal Investigator (or medically qualified nominee) considers the subject unfit for the study.
Male
20 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01197209
MTG-REIC-PC001
Yes
Momotaro-Gene Inc.
Momotaro-Gene Inc.
Mount Sinai School of Medicine
Principal Investigator: Simon Hall, MD Mount Sinai School of Medicine
Momotaro-Gene Inc.
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP